✦ LIBER ✦

Treatment of older patients with HER2-positive metastatic breast cancer with pertuzumab, trastuzumab, and docetaxel: subgroup analyses from a randomized, double-blind, placebo-controlled phase III trial (CLEOPATRA)

✍ Scribed by Miles, David; Baselga, José; Amadori, Dino; Sunpaweravong, Patrapim; Semiglazov, Vladimir; Knott, Adam; Clark, Emma; Ross, Graham; Swain, Sandra M.

Book ID: 121606141
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 282 KB
Volume: 142
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-013-2710-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pertuzumab, trastuzumab, and docetaxel f

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

✍ Swain, Sandra M; Kim, Sung-Bae; Cortés, Javier; Ro, Jungsil; Semiglazov, Vladimi 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 399 KB

Incidence of central nervous system meta

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomized phase III study CLEOPATRA

✍ Swain, S. M.; Baselga, J.; Miles, D.; Im, Y.- H.; Quah, C.; Lee, L. F.; Cortes, 📂 Article 📅 2014 🏛 Oxford University Press 🌐 English ⚖ 145 KB

Phase II Trial of Weekly Docetaxel, Vino

Phase II Trial of Weekly Docetaxel, Vinorelbine, and Trastuzumab in the First-Line Treatment of Patients with HER2-Positive Metastatic Breast Cancer

✍ Jeffrey R. Infante; Denise A. Yardley; Howard A. Burris III; F. Anthony Greco; C 📂 Article 📅 2009 🏛 CIG Media Group, LP. 🌐 English ⚖ 120 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

AVEREL: A Randomized Phase III Trial Eva

AVEREL: A Randomized Phase III Trial Evaluating Bevacizumab in Combination With Docetaxel and Trastuzumab As First-Line Therapy for HER2-Positive Locally Recurrent/Metastatic Breast Cancer

✍ Gianni, Luca (author);Romieu, Gilles H. (author);Lichinitser, Michail (author);S 📂 Article 📅 2013 🏛 American Society of Clinical Oncology 🌐 English ⚖ 205 KB

Multicenter Phase III Randomized Trial C

Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens

✍ Valero, V.; Forbes, J.; Pegram, M. D.; Pienkowski, T.; Eiermann, W.; von Minckwi 📂 Article 📅 2011 🏛 American Society of Clinical Oncology 🌐 English ⚖ 257 KB